Journal
EVIDENCE-BASED MENTAL HEALTH
Volume 19, Issue 2, Pages 35-38Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/eb-2016-102355
Keywords
-
Categories
Funding
- Janssen Pharmaceutical
- Avanir Pharmaceutical
- Icahn School of Medicine at Mount Sinai from Alkermes
- Astra Zeneca
- Brainsway
- Euthymics
- Neosync
- Roche
- Shire
Ask authors/readers for more resources
Approximately one-third of patients with major depressive disorder (MDD) do not respond to existing antidepressants, and those who do generally take weeks to months to achieve a significant effect. There is a clear unmet need for rapidly acting and more efficacious treatments. We will review recent developments in the study of ketamine, an old anaesthetic agent which has shown significant promise as a rapidly acting antidepressant in treatment-resistant patients with unipolar MDD, focusing on clinically important aspects such as dose, route of administration and duration of effect. Additional evidence suggests ketamine may be efficacious in patients with bipolar depression, post-traumatic stress disorder and acute suicidal ideation. We then discuss the safety of ketamine, in which most neuropsychiatric, neurocognitive and cardiovascular disturbances are short lasting; however, the long-term effects of ketamine are still unclear. We finally conclude with important information about ketamine for primary and secondary physicians as evidence continues to emerge for its potential use in clinical settings, underscoring the need for further investigation of its effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available